Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
May 2019
Historique:
received: 22 11 2018
revised: 06 01 2019
accepted: 29 01 2019
pubmed: 9 2 2019
medline: 27 8 2019
entrez: 9 2 2019
Statut: ppublish

Résumé

Numerous factors can affect multiple sclerosis (MS) patients' quality of life (QoL). We investigated how physical impairment, upper extremity function, cognitive impairment, cognitive reserve, symptoms of psychological distress, depression, fatigue as well as age and disease duration contribute to patient-reported measures of QoL in relapse-remitting MS (RRMS) and progressive MS (PMS). 39 patients with RRMS and 16 patients with PMS were evaluated for physical impairment (EDSS assessed by a neurologist), upper extremity function (9-hole peg test), cognitive deficits (broad neuropsychological test battery), cognitive reserves (highest obtained degree of education and vocabulary), symptoms of psychological distress (Symptom Checklist-90-R), depression (Beck Depression Inventory) and fatigue (Fatigue Scale for Motor and Cognitive Functions). The effects of these variables on QoL, as measured with the EQ-5D-3L, were tested with a multivariate analysis of variance. Degree of education, MS disease type, disease duration, BDI and SCL-90-R-scores affected significantly the EQ-5D index. Post-hoc analysis revealed that patients with university education, RRMS, shorter disease duration as well as less depression and psychological distress symptoms had significantly higher EQ-5D indices. No significant effects were observed for measures of physical disability, cognitive impairment or fatigue. Depression and psychological distress symptoms are among the factors with the most essential impact on subjective well-being in MS patients. Since they can be targeted by both psychopharmacological and psychotherapeutic treatment, focusing on mental comorbidity could substantially increase QoL in MS.

Sections du résumé

BACKGROUND BACKGROUND
Numerous factors can affect multiple sclerosis (MS) patients' quality of life (QoL). We investigated how physical impairment, upper extremity function, cognitive impairment, cognitive reserve, symptoms of psychological distress, depression, fatigue as well as age and disease duration contribute to patient-reported measures of QoL in relapse-remitting MS (RRMS) and progressive MS (PMS).
METHODS METHODS
39 patients with RRMS and 16 patients with PMS were evaluated for physical impairment (EDSS assessed by a neurologist), upper extremity function (9-hole peg test), cognitive deficits (broad neuropsychological test battery), cognitive reserves (highest obtained degree of education and vocabulary), symptoms of psychological distress (Symptom Checklist-90-R), depression (Beck Depression Inventory) and fatigue (Fatigue Scale for Motor and Cognitive Functions). The effects of these variables on QoL, as measured with the EQ-5D-3L, were tested with a multivariate analysis of variance.
RESULTS RESULTS
Degree of education, MS disease type, disease duration, BDI and SCL-90-R-scores affected significantly the EQ-5D index. Post-hoc analysis revealed that patients with university education, RRMS, shorter disease duration as well as less depression and psychological distress symptoms had significantly higher EQ-5D indices. No significant effects were observed for measures of physical disability, cognitive impairment or fatigue.
CONCLUSIONS CONCLUSIONS
Depression and psychological distress symptoms are among the factors with the most essential impact on subjective well-being in MS patients. Since they can be targeted by both psychopharmacological and psychotherapeutic treatment, focusing on mental comorbidity could substantially increase QoL in MS.

Identifiants

pubmed: 30735970
pii: S2211-0348(19)30051-3
doi: 10.1016/j.msard.2019.01.049
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

33-37

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Yavor Yalachkov (Y)

University Hospital Frankfurt, Department of Neurology, Frankfurt am Main, Germany. Electronic address: yavor.yalachkov@kgu.de.

Dilara Soydaş (D)

University Hospital Frankfurt, Department of Neurology, Frankfurt am Main, Germany.

Johannes Bergmann (J)

University Hospital Frankfurt, Department of Neurology, Frankfurt am Main, Germany.

Stefan Frisch (S)

University Hospital Frankfurt, Department of Neurology, Frankfurt am Main, Germany; Institute of Psychology, Goethe-University, Frankfurt am Main, Germany.

Marion Behrens (M)

University Hospital Frankfurt, Department of Neurology, Frankfurt am Main, Germany.

Christian Foerch (C)

University Hospital Frankfurt, Department of Neurology, Frankfurt am Main, Germany.

Johannes Gehrig (J)

University Hospital Frankfurt, Department of Neurology, Frankfurt am Main, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH